SCHEMBL3361014

SCHEMBL3361014

Cc1c(OCc2ccccc2)c(=O)ccn1C(OCc1ccccc1)C(C)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.56
▸ KMT2A Q03164 4/20 0.56
▸ HTT P42858 2/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ HPGD P15428 1/20 0.56
▸ NPC1 O15118 1/20 0.52
▸ NPSR1 Q6W5P4 2/20 0.51
▸ LMNA P02545 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ MAPT P10636 2/20 0.39
▸ MAPK14 Q16539 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ GLRA1 P23415 1/20 0.36
▸ GRM2 Q14416 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3360281 0.85 HTT (0.44) MEN1KMT2AHTTSMN1; SMN2ALDH1A1
SCHEMBL14311723 0.81 HTT (0.63) MEN1KMT2AHTTSMN1; SMN2ALDH1A1
SCHEMBL30580526 0.80 MEN1 (0.59) MEN1KMT2AHTTSMN1; SMN2ALDH1A1
SCHEMBL30580525 0.80 MEN1 (0.59) MEN1KMT2AHTTSMN1; SMN2ALDH1A1
SCHEMBL23969870 0.78 MEN1 (0.56) MEN1KMT2AHTTSMN1; SMN2ALDH1A1
SCHEMBL29243887 0.78 MEN1 (0.60) MEN1KMT2AHTTSMN1; SMN2ALDH1A1
SCHEMBL29243885 0.78 MEN1 (0.60) MEN1KMT2AHTTSMN1; SMN2ALDH1A1
SCHEMBL29243825 0.76 MEN1 (0.56) MEN1KMT2AHTTSMN1; SMN2ALDH1A1
SCHEMBL29243824 0.76 MEN1 (0.56) MEN1KMT2AHTTSMN1; SMN2ALDH1A1
SCHEMBL30580520 0.76 MEN1 (0.56) MEN1KMT2AHTTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100076199-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIDONE CARBOXYLIC ACIDS GE HEALTHCARE AS (NO) 2010-03-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076199-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIDONE CARBOXYLIC ACIDS PNPO, PGD, PDXK MEN1 694/4885KMT2A 2743/4885HTT 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback